SCHOTT Pharma AG & Co. KGaA : Positive newsflow on FY 24 guidance during the H1 results conference call
>FY 24 sales guidance is not limited to the lower end of the range any more - The most important topic of the H1 conference call was that the CFO, Dr Almuth Steinkühler, changed the tone on the 2024 sales guidance. Previously the company limited the guidance to the low end of its 9-11% sales growth target for FY 24 as FY 23 came in stronger than anticipated and therefore comps were challenging. At the conference call, the CFO explicitly emphasised that the full range ...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.